Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2018—Beckman Coulter Diagnostics is collaborating with Johns Hopkins Medicine to explore co-innovation initiatives with the goal of developing and commercializing novel solutions that address challenges in health care.
November 2018—Qiagen and Hamilton Robotics announced a collaboration to improve processing of Qiagen’s QuantiFeron-TB Gold Plus diagnostic test through the integration of Hamilton’s Microlab Star automated liquid handling workstation into the QFT-Plus assay workflow.
November 2018—Binding Site’s Immunologicals Group has introduced highly purified Borrelia and chikungunya glycoprotein antigens for use in IVD manufacturing and research applica-tions and as a component within solid phase ELISA-based immunoassay test procedures.
November 2018—Singulex introduced its Singulex Clarity C. diff toxin A/B assay. The assay is a rapid, high-sensitivity, high-precision, one-step solution to C. difficile toxin testing that matches the sensitivity and specificity of cell cytotoxicity neutralization assay, the company reports, “giving it the potential to reduce the false-positives of PCR and the false-negatives of current, less sensitive toxin immunoassays.”
November 2018—Heathrow Scientific introduced its MagFuge high-speed centrifuge and magnetic stirrer in one unit. The MagFuge features a back-lit digital display and one button programming. Three rotors are included, two for centrifugation (a 12 place for 1.5/2.0 mL tubes and a six place for 5 mL tubes, with adapters for additional tube sizes) and one for stirring that includes two rare earth magnets for high-performance mixing.
November 2018—Sakura Finetek USA launched the Accu-Cut SRM 300 LT manual microtome. New features include a four-color LED backlit 3D precision chuck, which increases the contrast between specimens and paraffin without warming the block. Users can visualize translucent biopsies in the block using one or a combination of the four LED colors.
November 2018—ARUP Laboratories has added seven new genes to its Solid Tumor Mutation Panel by Next Generation Sequencing. The genes added are CTNNB1 (beta catenin), DDR2, MAP2K1, MTOR, NTRK1, ROS1, and TERT.
November 2018—Siemens Healthineers announced that Cincinnati Children’s Hospital Medical Center is the first children’s hospital worldwide to install the Atellica Solution immunoassay and clinical chemistry analyzers.
October 2018—Kurin announced the results of clinical data from hospitals that use its FDA-cleared blood culture diversion device. In studies conducted at Crouse Hospital, Syracuse, NY, and Bayfront Health, St. Petersburg, Fla., the hospitals saw an overall reduction—56 percent and 54 percent, respectively—in contaminated blood cultures inclusive of all cultures drawn with or without the device. When a Kurin set was used in the blood collection, Crouse saw an 89 percent reduction in contaminated blood cultures and Bayfront a 90 percent reduction in contaminated cultures. In both cases, the hospitals were already below the three percent national contamination rate benchmark when they began using Kurin. Using the company’s passive diversion technology, the hospitals’ overall contamination rates decreased to 0.8 percent and 1.2 percent, respectively. The company has also released a five-minute documentary film titled Cry Wolf: The Consequences of Blood Culture Contamination. The film addresses the prevalence of blood culture contamination, the clinical impact on patients, and the steep associated costs for hospitals. Cry Wolf can be viewed at www.betterbloodcultures.com.
October 2018—Techlab received FDA 510(k) clearance for its H. Pylori Quik Chek and H. Pylori Chek tests. The tests aim to offer quick and reliable detection of Helicobacter pylori–specific antigen in human fecal specimens.
